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To analyse the phenotype of breast tumours that express oestrogen receptor-b (ERb) alone tissue microarrays were used to
investigate if ERb isoforms are associated with specific prognostic markers and gene expression phenotypes in ERa-negative tumours.
ERa-negative tumours were positive for ERb1 in 58% of cases (n¼122/210), total ERb in 60% (n¼115/192) and ERb2/cx in 57% of
cases (n¼114/199). Oestrogen receptor-b1 and total ERb were significantly correlated with Ki67 (r¼0.28, Po0.0001, n¼209;
r¼0.29, Po0.0001, n¼191) and with CK5/6, a marker of the basal phenotype (r¼0.20, P¼0.0106, n¼170; r¼0.18, P¼0.0223,
n¼158). ERb2/cx was strongly associated with p-c-Jun and NF-kBp65 (r¼0.53, Po0.0001, n¼93; r¼0.35, Po0.0001, n¼176).
This study shows that a range of ERb isoform expression occurs in ERa-negative breast tumours. While expression of ERb1, total and
ERb2/cx are correlated, individual forms show associations with certain phenotypes that suggest different roles in subsets of ERa-
negative cancers. Based on our in vivo observations, ERb may have the potential to become a therapeutic target in the specific
subcohort of ERa-negative breast cancers.
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Oestrogen receptor-a (ERa) is an important biomarker of response
to endocrine therapy in breast cancer (Osborne, 1998). However,
the definition of ER status in breast cancer is potentially more
complex, since there are now two known ERs, ERa and ERb.
Oestrogen receptor-b is expressed in both normal and neoplastic
human breast tissue (Leygue et al, 1998; Mann et al, 2001; Murphy
et al, 2002; Fuqua et al, 2003; Skliris et al, 2003) but its role in
either tissue remains unknown. Several isoforms of ERb have been
identified, which are either exon deletions or products of
alternative splicing which result in proteins that are truncated at
the C-terminus and do not bind ligand (Lu et al, 1998; Ogawa et al,
1998; Fuqua et al, 1999; Leygue et al, 1999; Saunders et al, 2002).
Thirty percent of breast tumours are classified as ER negative at
the time of diagnosis and will be mostly resistant to endocrine
therapy (Lapidus et al, 1998; Osborne, 1998). However, the
previous assays used for ER measurement favoured the detection
of ERa (Harvey et al, 1999; Brouillet et al, 2001) and we now know
that some of these tumours express ERb (Murphy et al, 2003).
Considering studies where ERb protein expression was deter-
mined, the pooled data sets were used to estimate the frequency of
ERb and ERa status in breast cancers (Murphy et al, 2003). The
most frequently occurring tumour type is ERaþ/ERbþ (B60%)
with similar frequencies of the other three ER phenotypes (ERaþ/
ERb ;E R a /ERbþ;E R a /ERb ) at 10–20% (Murphy et al,
2003). It is important to note that there are two groups of ERb-
positive breast tumours, those with coexpression of ERa and those
expressing ERb alone. The former is the most frequent and
probably dominates the analysis of most previously reported
correlative studies, and hence the positive association of ERb
expression generally with good prognosis and good clinical
outcome with respect to tamoxifen treatment (Mann et al, 2001;
Omoto et al, 2001; Murphy et al, 2002; Iwase et al, 2003; Esslimani-
Sahla et al, 2004; Fleming et al, 2004; Hopp et al, 2004; Myers et al,
2004; Nakopoulou et al, 2004). There is little data exploring
tumours that express ERb alone. Under the current system of
determining ER status, these are classified clinically as ER
negative, and currently there are few markers for further
subclassifying these ERa-negative cancers. Nevertheless recent
data show that some invasive breast cancers expressing the basal
cytokeratin CK5/6, may represent one ERa-negative subset, known
as the basal epithelial phenotype and show a relatively poor
prognosis (Perou et al, 2000; Sorlie et al, 2001, 2003; Nielsen et al,
2004). In the present study, we have investigated the level and
frequency of expression of ERb in ER-negative tumours and
its association with the basal phenotype and other established
markers of prognosis, such as indicators of signal transduction
pathways, proliferative and apoptotic markers.
MATERIALS AND METHODS
Tissues
All invasive breast cancers used in the current study were obtained
from the Manitoba Breast Tumour Bank (MBTB, Department of
Pathology, University of Manitoba) (Watson et al, 1996), which
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soperates with approval from the Faculty of Medicine, University
of Manitoba, Research Ethics Board. All samples included in the
MBTB are rapidly frozen at  701C immediately after surgical
removal. A portion of the frozen tissue from each case is then
processed to create matched formalin-fixed paraffin-embedded
and frozen tissue blocks.
Clinical–pathological characteristics of the patient cohort
Cases selected for this study were on the basis of (a) minimum
patient follow-up of 36 months, (b) invasive components
occupying more than 20% of the tumour section, while normal
epithelial areas comprised no more than 10% of the epithelial
content and (c) ER-negative status as defined by ligand binding
analysis (LBA) of p3fmolmg
 1 protein. The criteria for
interpretation of the variables were as follows: (a) PR-positive
status was defined as 415fmolmg
 1 protein by LBA; (b) grade,
(Nottingham system), was assigned to low (scores 3–5), moderate
(scores 6 and 7), or high (scores 8 and 9) categories; (c) tumour
size, was assigned either small (p2cm) or large (42cm)
categories; (d) tumour inflammation was assessed by a scale from
1 to 5 and then assigned to low (scores 1–3) or high (scores 4 and
5) categories. All patients were treated with surgery and for 29
patients this was the only treatment regimen. The remaining
patients received a variety of additional treatments, hormonal
therapy (28), chemotherapy (49) or radiotherapy (9) alone, or
combination of radiation followed by hormonal therapy (8),
hormonal and chemotherapy (16), hormonal and chemotherapy
(19) or chemotherapy (46), and for 6 patients the treatment regime
was unknown.
Tissue microarrays
The histopathology of all MBTB cases has been assessed and
entered into a computerised database to enable selection based on
composition of the tissue as well as clinical–pathological
parameters. After selection, cases were rereviewed on H&E
sections by a breast histopathologist (PHW). Tissue microarrays
(TMAs) from a total cohort of 255 ERa negative (ERa–255TMA),
primary invasive ductal breast carcinomas were constructed.
Briefly, duplicate core tissue samples (0.6mm diameter), were
taken from selected areas of maximum cellularity for each tumour
with a tissue arrayer instrument (Beecher Instruments, Silver
Spring, MD, USA). Although the TMA consisted of 255 cases
of ER-negative tumours as determined by LBA (ERþ
43fmolmg
 1protein), 39 of these were subsequently found to
be ERaþ by immunohistochemistry (IHC) and were excluded
from the later analysis.
Immunohistochemical assay
Serial sections (5mm) of the ERa–255TMA were cut, mounted on
Fisherbrand Superfrost/plus slides (Fisher Scientific, USA) and
stained using IHC with commercially available specific antibodies
(Table 1). Further details of the three specific ERb antibodies are as
follows: ERb1 (polyclonal, GC17/385P, Biogenex, CA, USA, raised
to peptide containing amino acids 449–465) at 1:100 dilution;
total ERb (monoclonal, 14C8, Genetex, TX, USA, raised to peptide
containing amino acids 1–153) at 1:100; ERb2/cx (mouse
monoclonal, clone 57/3, raised to synthetic peptide derived from
the specific C-terminus of hERb2/cx isoform; Serotec, UK) used at
1:20. Briefly, sections were dewaxed in two xylene baths (5min
each), taken through a series of alcohols (100, 95, 70%), rehydrated
in distilled water and then submitted to heat-induced antigen
retrieval for 8min in the presence of a citrate buffer (CC1 mild/
standard, Ventana Medical Systems, AZ, USA) using an automated
tissue immunostainer (Discovery Staining Module, Ventana
Medical Systems, AZ, USA). The staining protocol was set to
‘Mild and Standard Cell Conditioning’ procedure for all antibodies.
Primary antibodies were applied for 60min (except for NF-kBp65
which were applied for 30min) while secondary antibodies
were incubated for 32min. Initial dilutions quoted above were
diluted further 1:3 with buffer dispensed onto the slide with the
primary antibody. Primary antibodies were omitted for negative
controls.
Total ERb IHC was performed manually; sections were
microwaved in the presence of 0.01 M citrate buffer, pH 6.0, for
20min at full power (Danby, ON, Canada, model DMW 1001W,
800W maximum output). Sections were blocked and then
incubated using an ERb monoclonal antibody (14C8, Genetex,
TX, USA) at 1:100 dilution in a humidified chamber at 41C
overnight, as previously described (Skliris et al, 2002, 2003; Fuqua
et al, 2003). Following incubation with biotinylated goat anti-
mouse antibody for 60min at 1:200 (Jackson ImmunoResearch
Laboratories, PA, USA) and with the Vectastain ABC kit (Vector
Laboratories, CA, USA) for 45min, total ERb protein was
visualised with 3,30-diaminobenzidine (DAB, Sigma-Aldrich, ON,
Canada). Slides were scored semiquantitatively under a standard
light microscope. Images were captured using Polaroid DMC-2
software (version 2.0.1, Polaroid, MA, USA).
Quantification technique and marker selection
The expression of ERb isoforms (full-length-ligand binding ERb1,
total ERb and ERb2/cx) and other prognostic markers was
assessed using semiquantitative scoring (H-scores). H-scores
derive from a semiquantitative assessment of both staining
intensity (scale 0–3) and the percentage of positive cells (0–
Table 1 Details of antibodies used for IHC in the present study
Antibody Antibody clone Supplier Antibody dilution Incubation details Antigen retrieval method
a
ERb 385P polyclonal Biogenex, USA 1:100 1h @ 421C CC1
Total ERb 14C8 Genetex, USA 1:100 O/N @ 41C 0.01 M citrate pH 6.0
b
ERb2/cx 57/3 Serotec, UK 1:20 1h @ 421C CC1
CK5/6 D5/16134 Zymed Labs, USA 1:20 1h @ 421C CC1
Her2/neu CB11 Novocastra, UK 1:50 1h @ 421C CC1
EGFR 3C6 Ventana Systems, USA Dispensed 30min @ 421C Protease 1
c
Ki67 MIB-1 Dako, Canada 1:50 1h @ 421C CC1
Caspase-3 Asp175 Cell Signaling, USA 1:100 1h @ 421C CC1
p-c-Jun 822 SantaCruz, USA 1:100 1h @ 421C CC1
NF-kBp65 8008 SantaCruz, USA 1:625 30min @ 421C CC1
ERa 6F11 Novocastra, UK 1:50 1h @ 421C CC1
ERa, oestrogen receptor-b; IHC, immunohistochemistry.
aMild and standard cell conditioning, using CC1 antigen retrieval buffer (Ventana Medical Systems, AZ, USA).
bIHC
procedure performed manually.
cVentana Automated Systems using protease-1 enzyme for antigen retrieval.
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s100%), which when multiplied, generates a score ranging from 0
to 300. Tissue microarray staining was evaluated by two authors
(GPS, PHW) independently and where discordance was found,
cases were re-evaluated together to reach agreement. For the
primary categorical analysis, staining and cutoff points to
distinguish low from high expression for each marker were as
follows: only nuclear staining was evaluated for ERb1, total ERb
and ERb2/cx isoforms and since there is no agreement or clinical
relevant cutoff IHC-scores for ERb isoforms reported in the
literature, several IHC-score cut-points equivalent to absent
staining, the 25th percentile and median IHC-score values were
tested in statistical analysis. Ki67, caspase-3 (markers of prolifera-
tion and apoptosis, respectively) and CK5/6 (a marker of the basal
phenotype) were scored as previously described (Perou et al, 2000;
Wykoff et al, 2001; Foulkes et al, 2004; El-Rehim et al, 2005). Since
NF-kB has been associated previously with more aggressive breast
cancer (Biswas et al, 2004) and both NF-kB and AP-1 have been
shown to interact differentially with ERa and ERb (Paech et al,
1997; An et al, 1999) we have also assessed the relationship of ERb
to these pathways in ERa-negative tumours. For NF-kB/p65
nuclear staining was assessed and multiple H-score cutoffs were
tested. P-c-Jun, a marker of AP-1 activity, was defined by nuclear
staining and an H-score of 40.
Statistical analysis
Associations between ERb isoforms and other clinical–pathologi-
cal variables were tested using contingency methods (Fisher’s
exact test). Correlations were assessed by the Spearman’s rank
correlation test (r). Mann–Whitney rank sum tests, two-sided
were also used to evaluate variables. Survival analyses
were perfomed using the log rank test to generate Kaplan–Meier
curves. Overall survival was defined as the time from initial
surgery to the date of death attributable to breast cancer. Relapse-
free survival was defined as the time from initial surgery to the
date of clinically documented local or distant disease recurrence
or death attributed to breast cancer. GraphPad Prism 4.02 version
statistics software (GraphPad, San Diego, CA, USA) was used to
perform all analyses.
RESULTS
Validation of ERb antibodies
Three antibodies previously validated to detect ERb related
proteins were used in this study (Fuqua et al, 1999; Leav et al,
2001; Saunders et al, 2002). GC17/385P (Leav et al, 2001) was
raised to a C-terminal epitope of the wild-type ligand binding
isoform of ERb, generally referred to as ERb1. 14C8 antibody
(Fuqua et al, 1999) was raised to an N-terminal epitope which
would be found in both ERb1 and multiple C-terminal truncated
nonligand binding forms of ERb and therefore would detect
multiple known ERb isoforms including ERb1 and ERb2cx. Hence
we refer to it as detecting ‘total’ ERb. The antibody used to detect
the nonligand isoform ERb2/cx (Saunders et al, 2002) has been
previously validated by IHC and immunoblotting (Saunders et al,
2002). However, we have also validated the antibody further at the
IHC level, by using MCF7 breast cancer cell lines, which have been
engineered to overexpress ERb1o rE R b2/cx, after induction with
the tetracycline analogue doxycycline (Murphy et al, 2005). Agar
embedded cell pellets (Riera et al, 1999), formalin-fixed and
paraffin-embedded (Adeyinka et al, 2002) from only the doxy-
cycline treated cells expressing ERb2/cx but not ERb1 or controls
were found to show nuclear staining with the specific ERb2/cx
antibody under the same IHC conditions described above for the
human breast tumours (Figure 1A).
ERb isoform expression in ERa-negative human breast
tumours
Serial sections of the ERa–255TMA were stained with specific
antibodies for ERb1, total ERb, and ERb2/cx using IHC. Nuclear
staining could be observed with ERb1 and total ERb antibodies in
epithelial cells in our series of invasive cancers (Figure 2). Strong
nuclear staining in both normal and neoplastic breast tissues for
ERb2/cx isoform was often observed (Figure 1B). Using the 25%
percentile of IHC-scores to define positive status for ERb1, total
ERb and ERb2/cx, we observed that 58% of ERa-negative tumours
were positive for ERb1( n¼122/210), 60% positive for total ERb
(n¼115/192) and 57% of cancers were positive for ERb2/cx
(n¼114/199; Table 2).
ERb1 was significantly correlated with both total ERb and ERb2/
cx (r¼0.28,P o0.0001, n¼189; r¼0.27, P¼0.0002, n¼196,
respectively; Table 3). The same relationship was evident in
categorical analysis using a variety of cutoff values for contingency
analysis, where ERb1 was also significantly associated with ERb2/
cx and total ERb (P¼0.0083, 410; P¼0.0016, 0.0391; 410, 425
respectively, Fishers exact test). Using a cut-point for ERb1o f
either 410 or 425, median levels of total ERb expression were
significantly higher in ERb1-positive vs -negative tumours
(P¼0.0026 and P¼0.011, Mann–Whitney rank sum tests, two-
sided). Similarly using the same two cut-points for ERb1 positivity
median levels of ERb2/cx expression were significantly higher in
ERb1-positive vs -negative tumours (P¼0.0024 and P¼0.022,
respectively Mann–Whitney rank sum tests). These data suggest
frequent coexpression of multiple ERb isoforms in breast tumours.
Relationship of ERb isoform expression with markers of
proliferation and apoptosis in ERa-negative human breast
tumours
ERb1( r¼0.28, Po0.0001, n¼209) and total ERb (r¼0.29,
Po0.0001, n¼191; Table 3) were positively correlated with Ki67,
a marker of proliferation, which was detected in the nuclei of ERa-
negative tumours (Figure 2). Contingency analyses also showed
that ERb1 and total ERb were associated with Ki67 (data not
shown). Using the median Ki67 IHC-score as a cutoff to define low
Ki67 (p25) and high Ki67 (425), the median level of ERb1
expression was significantly lower in low Ki67 expressors (median
Figure 1 (A) Validation of ERb2/cx antibody (mouse monoclonal, clone 57/3, Serotec, UK): (a) Serotec clone 57/3 antibody staining of section from cell
pellet of doxycycline treated tet-on-MDA231 cells stably overexpressing ERb2/cx, magnification  500; (b) same as (a), magnification  1250; (c) Serotec
clone 57/3 antibody staining of section from cell pellet of doxycycline treated tet-on-MCF7 cells stably overexpressing ERb2/cx, magnification  500; (d)
same as (c), magnification  1250; (e) Serotec clone 57/3 antibody staining of section from cell pellet of a separate clone of doxycycline treated tet-on-
MCF7-cells stably overexpressing ERb2/cx, magnification  500; (f) same as (e), magnification  1250; (g) Serotec clone 57/3 antibody staining of section
from cell pellet of doxycycline treated tet-on-MCF7 vector alone control cells, magnification  500; (h) same as (g), magnification  1250; (i) Serotec clone
57/3 antibody staining of section from cell pellet of doxycycline treated MCF7 stably overexpressing ERb1 (Murphy et al, 2005), magnification  500. (B)
Expression of ERbcx/2 in ERa-negative invasive tumours and normal breast tissue detected by IHC is demonstrated in representative panels. (a) Tumour
core stained with the specific ERbcx/2 antibody (high H-score, 270); (b) tumour stained for ERbcx/2 (low H-score, 25); (c) tumour core showing negative
staining for ERbcx/2 H-score, 0); (d) normal breast tissue showing strong, nuclear ERbcx/2 protein expression; (e) nuclear ERbcx/2 expression in normal
breast ducts; (f) negative control (omission of ERbcx/2 antibody). Magnification  500 for a, b, c, and  1250 for d, e, f.
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P¼0.0008, Mann–Whitney rank sum test). Similarly the median
level of total ERb expression was significantly lower in low Ki67
expressors (median total ERb¼20) compared to high Ki67
expressors (median total ERb¼50; P¼0.0008, Mann–Whitney
rank sum test). No significant differences in ERb2/cx were found
between the low and high Ki67 groups.
However, high proliferation in primary tumours prior to
treatment, is often associated with high levels of apoptosis
(Lipponen et al, 1994; Lipponen, 1999; Parton et al, 2002).
Therefore, ERb expression was investigated with respect to a
marker of apoptosis, active caspase-3 (Parton et al, 2002). No
correlations were detected between ERb isoforms and caspase-3.
However, Ki67 expression was significantly correlated (r¼0.44,
Po0.0001, n¼211, Table 3) and associated (Po0.0001 Fisher’s
exact test; Mann–Whitney rank sum test) with caspase-3 in this
breast tumour cohort. These data suggest that ERb expression in
ERa-negative tumours is associated with markers of a high
proliferative index.
Relationship of ERb expression to basal epithelial
phenotype markers in ERa-negative human breast
tumours
Invasive breast cancers expressing the basal epithelial phenotype,
based on the consensus of the published literature from cDNA
microarray and IHC analyses, are ERa negative (Perou et al, 2000;
Sorlie et al, 2001; Vijver et al, 2002; Nielsen et al, 2004; El-Rehim
et al, 2005), CK5/6 positive (Sorlie et al, 2001; Korsching et al,
2002; Nielsen et al, 2004; Collett et al, 2005) and/or CK14
(El-Rehim et al, 2005) positive. The basal phenotype has also
been associated with mutated BRCA1 (Foulkes et al, 2003, 2004;
Sorlie et al, 2003; Collett et al, 2005). We were therefore interested
to determine the relationship of ERb expression in ERa-negative
tumours to markers of the basal epithelial phenotype. ERb1 and
total ERb expression were weakly correlated with CK5/6 (r¼0.20,
P¼0.010; n¼170; r¼0.18, P¼0.022, n¼158; Table 3). No
correlations were seen with ERb2/cx. These data support the
conclusion that many ERa-negative tumours expressing ERb are
associated with some markers of a basal epithelial phenotype in
breast cancer.
ERb2/cx expression in ERa-negative human breast
tumours
Despite the correlations and associations of ERb2/cx to ERb1 and
total ERb described above, ERb2/cx was not correlated with Ki67
nor activated caspase-3. However, ERb2/cx was strongly correlated
with p-c-Jun IHC-score (r¼0.53, Po0.0001, n¼93; Table 3).
Contingency analyses for ERb2/cx and p-c-Jun positivity, identi-
fied a significant association of ERb2/cx with p-c-Jun (Po0.0001,
Fisher’s exact test). When p-c-Jun expression level was examined
in relation to ERb2/cx status, p-c-jun IHC-score was significantly
lower in ERb2/cx-negative tumours (median p-c-Jun¼5) com-
pared to high ERb2/cx expressors (median p-c-Jun¼40;
Po0.0001, Mann–Whitney rank sum test).
Figure 2 Expression of ERb and Ki67 in ERa-negative tissue microarray cores. (A–C)E R a-negative tumour cores stained with the specific ERb1 antibody
(GC17/385P) showing negative, medium and high expression (a–c; H-scores of 0, 150 and 225, respectively); (D–F)E R a-negative tumour cores stained
with total ERb antibody (14C8) showing negative, low and high expression (H-scores of 0, 25 and 100, respectively); (G–I)E R a-negative tumour cores
showing negative, medium and high expression for Ki67, a proliferation marker (% positive, 0, 60 and 90%, respectively). Magnification  500.
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kBp65 (r¼0.35, Po0.0001, n¼176; Table 3). Using either the 25%
percentile (40) or the median (425) ERb2/cx IHC-score as cut-
points to define negative and positive ERb2/cx status the median
level of NF-kBp65 expression was significantly lower in negative/
low ERb2/cx expressors (median NF-kBp65¼50) compared to
high ERb2/cx expressors (median NF-kBp65¼100; Po0.0001,
Mann–Whitney rank sum test). Similar but weaker relationships
were found for total ERb. Using the median (425) total ERb IHC-
score as a cutoff to define negative and positive total ERb status the
median level of NF-kBp65 expression was significantly lower in
negative/low total ERb expressors (median NF-kBp65¼75)
compared to high total ERb expressors (median NF-kBp65¼100;
Po0.026, Mann–Whitney rank sum test). These data suggest that
ERb2/cx expression is associated with AP1 and NF-kB activity in
ERa-negative breast tumours. A relationship between total ERb
and p-c-Jun and NF-kBp65 was also demonstrated, and is likely to
reflect the influence of the ERb2/cx component of the total ERb
signal.
ERb isoform expression in relation to clinical and
pathological prognostic variables and survival
Only total ERb was associated with tumour grade (P¼0.03). No
other statistically significant associations between ER isoforms
and established prognostic variables such as tumour size, age at
diagnosis, node status, inflammation or progesterone receptor,
were observed (Table 2, showing associations with cut-points
equivalent to the 25th percentile).
Univariate survival analyses in relation to axillary nodal
status, size, grade, Ki67, active caspase-3, or basal phenotype,
showed a significant association only with nodal status (P¼0.024)
in this cohort of ERa-negative tumours. Furthermore no difference
in disease outcome (overall survival and relapse-free survival) was
Table 2 Clinical and pathological characteristics of the study cohort
ERb1 IHC-score
a Total ERb IHC-score
a ERb2/cx IHC-score
a
Patient characteristics Number (n)% P-value Number (n)% P-value Number (n)% P-value
ERa status
 ve 210 100 192 100 199 100
PR status
 ve 183 87 0.89 167 87 0.99 175 88 0.15
+ve 27 13 25 13 24 12
ERb1 status
+ve 122 58
 ve 88 42
Total ERb status
+ve 115 60
 ve 77 40
ERb2/cx status
+ve 114 57
 ve 85 43
Grade
Low 24 11 22 12 22 11
Mod 75 36 0.28 66 34 0.03 69 35 0.10
High 111 53 104 54 108 54
Tumour size (cm)
p2 58 28 0.68 55 29 0.50 55 28 0.42
42 152 72 137 71 144 72
Inflammation
Low 130 64 0.46 118 62 1.0 120 62 0.09
High 74 36 71 38 73 38
Age (years)
p50 71 34 0.82 65 34 0.54 66 33 0.71
450 139 66 127 66 133 67
Node status
0 100 48 0.67 92 48 0.57 94 47 0.08
1 110 52 100 52 105 53
Metastasis
Distant 72 73 0.76 64 74 0.72 65 73 0.61
Regional 18 18 15 17 15 17
Local 9 9 7 9 9 10
ERa, oestrogen receptor-b; IHC, immunohistochemistry.
a¼Using the 25th percentile of IHC-scores to define positive status for ERb1, total ERb and ERb2/cx (410, 410, 40).
P-value was obtained by using Fisher’s exact test. Values in bold are statistically significant (Po0.05).
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(Figure 3).
DISCUSSION
Several interesting observations have been made in the present
study concerning ERb isoform expression in ERa-negative breast
tumours. The first is that ERb1, total ERb and ERb2/cx isoforms
are frequently expressed in this cohort of ERa-negative breast
cancers. The second is that there is a significant correlation of
ERb1 and total ERb with Ki67, a marker of proliferation, which
is of particular interest. As this was not found when ERb2/cx
expression was assessed, it is likely that the correlation with total
ERb reflects the ERb1 component, although we cannot exclude the
existence of other, as yet unknown variant isoforms. Indeed, the
frequent expression of the ERb variant isoform, ERb5, in ERa-
negative breast tumours has recently been described (Poola et al,
2005), however, we did not have access to specific antibodies to
investigate this variant isoform in our breast tumour cohort. Our
data confirm and extend an observation made by Jensen et al
(2001), where the highest expression of either Ki67 and Cyclin A
was found in tumours that only expressed ERb, indicating that
ERb may be related to proliferation in breast cancer. Jensen’s
observation showing an association of ERb with Ki67, using an
antibody that recognised total ERb (Jensen et al, 2001), also
suggests that ERb isoforms are not only expressed in cells with the
potential to cycle but also can be expressed in cells that are cycling.
The existence of this relationship was reflected only in a very small
subset of seven tumours in the ERa-negative/ERb-positive cohort
in his study (Jensen et al, 2001), but a study by O’Neill et al (2004)
published during the execution of our study confirmed his
observation in a larger cohort (n¼167). However, results from
these latter studies came only from subset analysis of mixed
cohorts of ERa-positive and -negative tumours. Our study is the
only one so far exclusively focusing on ERa-negative cancers to
address the issue of ERb expression. The cohort used in our study
(n¼216) is the largest so far and included tumours that were all
selected to be ERa negative, both immunohistochemically and by
LBA. Thus, the relationship of ERb1 alone expression in human
breast cancer to Ki67, seems to be highly reproducible and
therefore likely offers a new significant insight into the possible
role of ERb1 in breast cancer. In contrast, this relationship is
generally not seen in ERa-positive/ERb-positive breast tumours
(Jarvinen et al, 2000; Mann et al, 2001; Omoto et al, 2001; Murphy
et al, 2002; Fuqua et al, 2003; Iwase et al, 2003; Fleming et al, 2004;
Hopp et al, 2004; Myers et al, 2004; Nakopoulou et al, 2004) and
therefore our data together with two other studies support the
conclusion that the role of ERb1 when expressed alone in human
breast cancers in vivo is likely quite different to when it is
coexpressed with ERa. Such data suggest that ERb1 may have a
direct role in proliferation in ERa-negative breast cancers, but this
is unproven.
The involvement of ERb isoforms in proliferation using cell
line models is unclear. Most cell line models in which ERb1 has
been stably expressed either inducibly or constitutively show that
overexpression of ERb1 inhibits proliferation irrespective of
whether it is coexpressed with ERa (Paruthiyil et al, 2004; Strom
et al, 2004; Murphy et al, 2005) or not (Lazennec et al, 2001; Cheng
et al, 2004). However, two studies using cell line models have been
published in which stable constitutive overexpression of ERb1
resulted in increased proliferation (Tonetti et al, 2003; Hou et al,
2004) although in the former publication the short form of ERb1
(truncated by 45 amino acids from the N-terminus) was used. Both
breast cancer cell lines used (MDA-MB-231 and MDA-MB-435)
are typically ERa negative and therefore can be considered to
represent the ERb alone expressing breast tumours cohort in vivo.
However, in another constitutive ERb overexpression model based
on the MDA-MB-231 cells, little or no effect on proliferation,
positive or negative, was seen (Rousseau et al, 2004). Such data
indicate that differences in potential cell line background, the type
of ERb isoforms expressed and experimental variables including
possibly clonal selection can influence the effect of ERb on
proliferation. However, in other cancer cells types where ERb1 has
been overexpressed, increased ERb1 is most often associated with
inhibition of proliferation and/or increased apoptosis (Qiu et al,
2002; Cheng et al, 2004). It is unclear, however, whether the
overexpression of ERb1 in experimental cancer cell line models, is
relevant to the levels of ERb1 seen in tumours in vivo, especially
since generally ERb1 expression is reduced in tumours compared
to normal tissues in multiple cancers (Foley et al, 2000; Roger et al,
2001; Skliris et al, 2003) leading to the suggestion that ERb1i s
a tumour-suppressor gene, and certainly would be consistent
with the hypothesis that it is antiproliferative (Weihua et al, 2000;
Forster et al, 2002; Paruthiyil et al, 2004). As well the possibility
exists that ERb1 may be frequently mutated and/or altered post-
translationally in breast cancers in vivo, although no published
data as yet address this issue to our knowledge.
ERb1 and total ERb isoforms were also significantly correlated
with CK5/6, a marker of the basal epithelial phenotype as defined
from DNA microarray and IHC analyses, predominantly as ERa
negative and CK5/6 positive (Sorlie et al, 2001; Korsching et al,
2002; Collett et al, 2005; El-Rehim et al, 2005). As ERb is found
widely expressed in the basal myoepithelium (Murphy et al, 2002;
Speirs et al, 2002) as well as in luminal epithelial cells in normal
human breast tissues, it is possible that many ER-negative breast
cancers expressing ERb are derived from a myoepithelial cell
lineage, and that ERb is a marker of this lineage. Interestingly, a
reduced myoepithelial cell layer is found in the lactating mammary
gland of the ERb knockout mouse in contrast to the wild-type
controls (Forster et al, 2002). This led to the hypothesis that ERb
may be involved in regulating pathways, which are required for the
differentiation of the myoepithelial cell lineage in the mammary
gland (Forster et al, 2002).
While proliferation and the basal phenotype have been
associated with poor survival, no differences in clinical outcome
were identified between high and low Ki67 or any markers of the
Table 3 Spearman rank correlations of ERb isoforms with other
prognostic markers
r (Spearman) P-value No. of cases (n) Correlation with
ERb1 0.27 0.0002 196 ERb2/cx
0.28 o0.0001 189 Total ERb
0.28 o0.0001 209 Ki67
0.20 0.010 170 CK5/6
ERb2/cx 0.44 o0.0001 178 Total ERb
0.53 o0.0001 93 p-c-Jun
0.35 o0.0001 176 NF-kBp65
Total ERb 0.29 o0.0001 191 Ki67
0.18 0.022 158 CK5/6
0.24 0.020 88 p-c-Jun
0.24 0.002 169 NF-kBp65
CK5/6 0.20 0.006 171 Ki67
0.19 0.014 159 NF-kBp65
0.23 0.006 133 EGFR
NF-kBp65 0.32 o0.0001 159 Her-2/neu
Caspase-3 0.44 o0.0001 211 Ki67
0.18 0.021 156 EGFR
ERa, oestrogen receptor-b; IHC, immunohistochemistry.
ERb in breast tumours in vivo
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sbasal phenotype in our ERa-negative breast cancer cohort. It is
possible that the lack of association of any of parameters
investigated here (ERb isoforms, Ki67 and caspase-3) with clinical
outcome (disease-free survival and overall survival) is confounded
by the variety of treatments the patient cohort later received. In
addition, most other studies where Ki67 has been examined as a
prognostic factor have included both ER-positive and ER-negative
tumours in their cohorts (Trihia et al, 2003). It should also be
noted that ERa-negative status in our cohort was defined by
negative IHC and ligand binding assay. This definition eliminated
15% of an initial ERa-negative series selected only on the basis
of ligand binding assay. A similar number of ERa IHC-negative
tumours have been found to be positive by ligand binding assay
(Huang et al, 1997). The basis for discrepancy between these two
ERa assays has been a subject of past discussion in the literature
(Huang et al, 1997), but is likely to reflect biological variables
rather than tissue selection or composition, because of the design
of our tumour bank. Therefore, the current study used stringently
defined ERa-negative tumours and so was enriched for a generally
more aggressive group of breast tumours.
In comparison to ERb1, the role of its variant, ERb2/cx, is even
more unclear. Transient expression studies using human ERb2/cx,
have shown that human ERb2/cx is unable to bind ligand and
when overexpressed sufficiently can inhibit ERa transcriptional
activity (Ogawa et al, 1998; Peng et al, 2003) but has little if any
effect on ERb1 activity. In breast cancer ERb2/cx has been
identified at both the RNA and protein levels (Saji et al, 2002;
Esslimani-Sahla et al, 2004), and now with another antibody
we have also shown the presence of ERb2/cx in both normal and
neoplastic breast tissue. Most studies previously published
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Figure 3 Kaplan–Meier graphs for ‘overall survival’ and ‘relapse-free survival-time to progression’ with respect to expression of ERb1( A and B), ERb2cx
(C and D) and total ERb isoforms (E and F, respectively). ERb1 overall survival (A), n¼210, low ERb1 events¼47, high ERb1 events¼60. ERb1 time to
progression (B), low ERb1 events¼48, high ERb1 events¼60. ERb2cx overall survival (C), n¼199, low ERb2cx events¼44, high ERb2cx events¼53.
ERb2cx time to progression (D), low ERb2cx events¼44, high ERb2cx events¼53. Total ERb overall survival (E), n¼192, low total ERb events¼40, high
total ERb events¼55. Total ERb time to progression, low total ERb events¼40, high total ERb events¼56.
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to normal breast tissue (Omoto et al, 2002; Palmieri et al,
2004) and the relative expression of the ERb2/cx to ERb1i s
likely to change during breast tumourigenesis. However, no studies
focusing only on ERa-negative tumours have been published.
A few studies have suggested hypotheses as to ERb2/cx function
due to observed correlations and association with other prognostic
markers and clinical outcome with or without treatment
(Omoto et al, 2002; Esslimani-Sahla et al, 2004; Palmieri et al,
2004). Esslimani-Sahla et al (2004) showed that ERb2/cx
expression was correlated with total ERb, which is in agreement
with our observation in our ERa-negative series. However,
among these studies contradictory conclusions have often
been reached (Saji et al, 2002; Esslimani-Sahla et al, 2004;
Palmieri et al, 2004). Our data suggest that in ERa-negative
tumours, ERb2/cx expression is significantly associated with
both increased AP-1 and NF-kB expression and that ERb1 may
not be associated with these activities. This suggests that
the different ERb isoforms may be involved in regulation
of distinct pathways in these tumours or alternatively there is
differential regulation of ERb isoforms by distinct pathways in
these tumours.
The absence of any significant correlations between ERb
isoforms and particularly total ERb with either overall or
relapse-free survival is also in agreement with some other
published studies (Hopp et al, 2004) but disagrees with other
studies where increased ERb has been associated with better
survival (Nakopoulou et al, 2004) and when patients were treated
with tamoxifen alone, where an association was shown with better
response to tamoxifen therapy (Murphy and Watson, 2006).
However, in these latter studies the majority if not all the tumours
assessed were ERa positive and so represent a different context
where ERb is coexpressed with ERa. In the current study we have
hypothesised that the function of ERb expressed alone will be
different to that when ERb is coexpressed with ERa, and therefore
we have looked at a distinct cohort of patients where their tumours
are ERa negative.
These data support the hypothesis that the role of ERb
expression is different when expressed alone, to its role when
coexpressed with ERa in human breast cancer. This is specifically
reflected in the present study, by the confirmation of a strong
relationship of ERb1 with Ki67 in ERa-negative tumours, such
that it seems likely that the addition of an ERb1 antagonist could
be a potentially useful therapy in specific subsets of breast cancer
patients in a clinical setting.
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